> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Layoffs Affect Product Development: Post
- URL: https://www.fdaweb.com/fda-layoffs-affect-product-development-post/
- Published: 2025-04-30T12:00:00.000Z
- Updated: 2026-09-14T15:10:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5159099

Four Skadden attorneys say the 4/1 layoff of 3,500 FDA employees will likely have the greatest impact on products in development because the agency may not be able to issue as much guidance as it had previously or provide feedback and updates on applications. Writing in an online [post](https://www.skadden.com/insights/publications/2025/04/trump-administrations-first-100-days/mass-layoffs-at-fda?ref=fdaweb.com), the attorneys say the reduction in force eliminated employees and offices in multiple FDA support areas including policy staff who write guidances and regulations; project managers who keep industry apprised of the status of application reviews, answer regulatory questions, and generally keep agency business running; scientists who test products for adulteration and develop much of the regulatory science underpinning FDA’s review standards; and communications staff who issue media statements, update the FDA Web site, and inform consumers about health risks and new product approvals.

“Even before the 4/1 layoffs, industry participants had noticed a decline in FDA’s responsiveness, especially to non-essential or routine questions,” the attorneys write. “The removal of staff who support the agency’s day-to-day operations will likely only aggravate that issue. The layoffs, combined with a potential redesign or elimination of user fee programs, will result in a paradigm shift for the way industry interacts with FDA.”

For products in development, the experience with FDA is likely to change in terms of feedback, pilot and other special programs, information requests, approval dates, review updates, and guidance and regulation, the post says.

While the changes are not likely to have the same impact on marketed products, the attorneys say, it is likely that reviews of efficacy, labeling, and manufacturing supplements may be disrupted or less predictable. And, although HHS says the layoffs will not affect inspections, the attorneys cite media reports that routine current good manufacturing practice inspections have become fewer and less frequent. They suggest there may also be a drop in Warning Letters.